The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 07, 2002

Filed:

May. 31, 1995
Applicant:
Inventors:

Michael L Diegel, Kent, WA (US);

Peter S Linsley, Seattle, WA (US);

Lisa K Gilliland, Seattle, WA (US);

Patricia A Moran, Seattle, WA (US);

Joyce M Zarling, Seattle, WA (US);

Jeffrey A Ledbetter, Seattle, WA (US);

Assignee:

Bristol-Myers Sqibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 1/628 ; C07K 1/646 ; A01N 1/02 ;
U.S. Cl.
CPC ...
C07K 1/628 ; C07K 1/646 ; A01N 1/02 ;
Abstract

An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric nonclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional non-HIV-1-producing T cells in the patient.


Find Patent Forward Citations

Loading…